Chinook Therapeutics
Atrasentan, an endothelin receptor antagonist small-molecule therapeutic for IgA nephropathy and rare kidney diseases
- Sector
- Biotech
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 32 pending · first 2021
- Rank in peer group#213 of 1449
Capital timeline
No federal awards or Form D filings are on record for this company.
Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.
Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards
Founder? Add funding contextStanding among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#213 · top 15%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 7 granted of 39- GrantedMethods Of Improving Renal FunctionUSPTOUS 12,582,631
- GrantedMethods Of Improving Renal FunctionUSPTOUS 12,521,369
- PendingMethods Of Treating Focal Segmental Glomerulosclerosis With AtrasentanUSPTOApplication 18867358
Show all 39 patent records
- Methods Of Improving Renal FunctionMar 24, 2026 · US 12,582,631Granted
- Methods Of Improving Renal FunctionJan 13, 2026 · US 12,521,369Granted
- Methods Of Treating Focal Segmental Glomerulosclerosis With AtrasentanNov 20, 2025 · Application 18867358Pending
- Methods Of Improving Renal FunctionSep 11, 2025 · Application 18884802Pending
- Methods Of Improving Renal FunctionJul 29, 2025 · US 12,370,174Granted
- Methods Of Improving Renal FunctionOct 22, 2024 · US 12,121,509Granted
- Methods Of Improving Renal FunctionJun 4, 2024 · US 11,998,526Granted
- Methods Of Reducing Disease FlaresNov 9, 2023 · Application 18223290Pending
- Substituted Pyrazolyl Compounds And Methods Of Use ThereofJun 15, 2023 · Application 17925126Pending
- Methods Of Improving Renal FunctionNov 8, 2022 · US 11,491,137Granted
- Methods Of Reducing Disease FlaresSep 29, 2022 · Application 17826759Pending
- Inhibiting Mesangial Cell ActivationSep 29, 2022 · Application 17826753Pending
- Methods Of Treating Kidney DiseasesSep 15, 2022 · Application 17826832Pending
- Combination Therapy For The Treatment Of CancerJul 7, 2022 · Application 16966514Pending
- Methods Of Treating Iga Nephropathy With AtrasentanNov 18, 2021 · Application 17363604Pending
- Compositions And Methods For Activating "stimulator Of Interferon Gene" - Dependent SignallingJun 22, 2021 · US 11,040,053Granted
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63402613Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63402646Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63402619Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication PCTUS2022032042Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63402640Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63402648Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63402690Pending
- Methods Of Treating Iga NephropathyApplication 63420305Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63346120Pending
- Methods Of Treating Focal Segmental Glomerulosclerosis With AtrasentanApplication 63343574Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63290019Pending
- Methods Of Treating Focal Segmental Glomerulosclerosis With AtrasentanApplication PCTUS2023022681Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication 63196339Pending
- Pyridinyl Indole Compounds And Methods Of Use ThereofApplication 63172551Pending
- Methods Of Treating Iga Nephropathy With AtrasentanApplication PCTUS2020065311Pending
- Methods Of Treating Iga Nephropathy With AtrasentanApplication 63125205Pending
- Methods Of Treating Iga Nephropathy With AtrasentanApplication 63084739Pending
- Methods Of Treating Iga Nephropathy With AtrasentanApplication 63072699Pending
- Substituted Indole Compounds And Methods Of Use ThereofApplication PCTUS2023031666Pending
- Methods Of Treating Iga Nephropathy With AtrasentanApplication 63005003Pending
- Methods Of Treating Iga Nephropathy With AtrasentanApplication 62949115Pending
- Dc-sign Antibody Conjugates Comprising Sting AgonistsApplication PCTUS2019058926Pending
- Methods Of Treating Iga NephropathyApplication PCTUS2023078096Pending
Related companies, and why
- Plexiform Bioscience Inc.Similar federal contract value in Biotech · null in contracts
- Genvor IncSimilar federal contract value in Biotech · null in contracts
- LAURENT PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- DUPAGE MEDICAL TECHNOLOGY, INC.Similar federal contract value in Biotech · null in contracts
- SEEDLING BIOSYSTEMS INC.Similar federal contract value in Biotech · null in contracts
- CREATIVE BIOTHERAPEUTICS, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .